Q-omics provides the consensus-scored EMID1 profile across patient tissues and cancer cell-line models. EMID1 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, EMID1 is differentially expressed in 10, with the highest sampling consensus in KIRP. Additionally, EMID1 RNA expression shows 18,126 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight UVM, KIRP, and ACC as cancer lineages where EMID1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for EMID1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes EMID1 survival associations across molecular data types. EMID1 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible EMID1 RNA expression–survival associations across cancer types. High EMID1 expression shows unfavorable associations in UVM, LIHC, ACC and LGG, but favorable associations in LUAD and READ. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for EMID1 RNA expression.
This table summarizes EMID1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10, while mass-spec protein shows differences in 2. The strongest signals are observed in KIRP for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for EMID1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. EMID1 shows lower tumor expression in KIRP, KICH, THCA and LUAD and higher tumor expression in LIHC and UCEC. The KIRP box plot shows higher EMID1 RNA expression in normal versus tumor tissue (log2 FC = −1.168, t-test p < 0.001).
This table shows molecular features associated with EMID1 in patient tissues and cancer cell lines. In patient samples, EMID1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, EMID1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
